MARKET

XCUR

XCUR

Exicure Inc
NASDAQ
0.6176
-0.0062
-0.99%
Closed 18:24 03/27 EDT
OPEN
0.6326
PREV CLOSE
0.6238
HIGH
0.6326
LOW
0.5846
VOLUME
22.01K
TURNOVER
0
52 WEEK HIGH
1.500
52 WEEK LOW
0.3647
MARKET CAP
5.34M
P/E (TTM)
0.4832
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at XCUR last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at XCUR last week (0311-0315)?
Weekly Report · 03/18 11:44
Weekly Report: what happened at XCUR last week (0304-0308)?
Weekly Report · 03/11 11:40
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NKGen Biotech (NASDAQ:NKGN) stock rose 18.0% to $2.16 during Thursday's pre-market session. The company's market cap stands at $47.2 million. Nutex Health stock increased by 15.32% and Avinger stock moved upwards by 13.51%. Avid Bioservices stock declined by 37.4% during the pre- market session.
Benzinga · 03/07 13:06
Weekly Report: what happened at XCUR last week (0226-0301)?
Weekly Report · 03/04 11:44
5 Value Stocks In The Healthcare Sector
A value stock traditionally has a lower price when compared to companies in the same industry. A low price-to-earnings multiple is a good indication that the company is undervalued. Benzinga Insights has selected five notable value stocks in the healthcare sector. The value stocks were selected based on quantified analysis.
Benzinga · 02/26 14:44
Weekly Report: what happened at XCUR last week (0219-0223)?
Weekly Report · 02/26 12:00
5 Value Stocks In The Healthcare Sector
What is a value stock? A value stock is traditionally defined in terms of how investors are valuing a company's future growth prospects. Spok Holdings has a low P/E multiples and is considered to be a notable value stock in the healthcare sector. The company's most recent dividend yield sits at 8.6%.
Benzinga · 02/19 14:42
More
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.

Webull offers Exicure Inc stock information, including NASDAQ: XCUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XCUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XCUR stock methods without spending real money on the virtual paper trading platform.